Prevalence and significance of DDX41 gene variants in the general population.

Autor:	Cheloor Kovilakam S; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Gu M; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Dunn WG; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom., Marando L; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Barcena C; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Department of Biochemistry and Molecular Biology, Universidad de Oviedo, Oviedo, Spain., Nik-Zainal S; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom., Mohorianu I; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Kar SP; Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.; Section of Translational Epidemiology, Division of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom., Fabre MA; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom., Quiros PM; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain., Vassiliou GS; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2023 Oct 05; Vol. 142 (14), pp. 1185-1192.
DOI:	10.1182/blood.2023020209
Abstrakt:	Germ line variants in the DDX41 gene have been linked to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) development. However, the risks associated with different variants remain unknown, as do the basis of their leukemogenic properties, impact on steady-state hematopoiesis, and links to other cancers. Here, we investigate the frequency and significance of DDX41 variants in 454 792 United Kingdom Biobank (UKB) participants and identify 452 unique nonsynonymous DNA variants in 3538 (1/129) individuals. Many were novel, and the prevalence of most varied markedly by ancestry. Among the 1059 individuals with germ line pathogenic variants (DDX41-GPV) 34 developed MDS/AML (odds ratio, 12.3 vs noncarriers). Of these, 7 of 218 had start-lost, 22 of 584 had truncating, and 5 of 257 had missense (odds ratios: 12.9, 15.1, and 7.5, respectively). Using multivariate logistic regression, we found significant associations of DDX41-GPV with MDS, AML, and family history of leukemia but not lymphoma, myeloproliferative neoplasms, or other cancers. We also report that DDX41-GPV carriers do not have an increased prevalence of clonal hematopoiesis (CH). In fact, CH was significantly more common before sporadic vs DDX41-mutant MDS/AML, revealing distinct evolutionary paths. Furthermore, somatic mutation rates did not differ between sporadic and DDX41-mutant AML genomes, ruling out genomic instability as a driver of the latter. Finally, we found that higher mean red cell volume (MCV) and somatic DDX41 mutations in blood DNA identify DDX41-GPV carriers at increased MDS/AML risk. Collectively, our findings give new insights into the prevalence and cognate risks associated with DDX41 variants, as well as the clonal evolution and early detection of DDX41-mutant MDS/AML. (© 2023 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu